Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2917 | SARS-CoV-2 convalescent plasma treatment Wiki | 1.00 |
drug3185 | Standard care Wiki | 0.33 |
drug2490 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
D018352 | Coronavirus Infections NIH | 0.03 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
The BBV152 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the efficacy, safety, and immunogenicity of BBV152 to prevent COVID-19 for up to 1 year after the second dose of BBV152.
Description: (RT-PCR positive) symptomatic cases of COVID-19.
Measure: First occurrence of Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19. Time: Day 42 to Month 12Description: (RT-PCR positive) symptomatic cases of COVID-19.
Measure: First occurence of Virologically confirmed (RT-PCR positive) symptomatic cases of COVID-19 based on the case definition for the secondary efficacy symptomatic endpoint. Time: Day 42 to Month 12Description: (RT-PCR positive) severe symptomatic cases of COVID-19.
Measure: Virologically confirmed (RT-PCR positive) severe cases of COVID-19 Time: Day 42 to Month 12Description: (RT-PCR positive) symptomatic cases of COVID-19
Measure: Virologically confirmed COVID-19 cases of any severity occurring among participants 18 through 59 years of age and ≥60 years of age. Time: Day 42 to Month 12Description: (RT-PCR positive) asymptomatic/symptomatic cases of COVID-19.
Measure: Virologically confirmed COVID-19 asymptomatic and symptomatic cases occurring from two weeks after the second vaccination. Time: Day 42 to Month 12Description: Solicited, Unsolicited, Serious Adverse Events
Measure: Reactogenicity and Safety Time: Day 42 to Month 12Description: Reported by participant/documented in hospital records throughout the trial.
Measure: The occurrence of enhanced respiratory disease episodes. Time: Day 42 to Month 12Description: Assessed based Wild-type SARS-CoV-2 Specific Neutralizing Antibody (nAb)
Measure: Immunogenicity: Lot-to-Lot consistency of three consecutive GMP Lots Time: Day 0 to Day 42Description: Specific Neutralizing Antibody (nAb)
Measure: Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) Time: Day 0 to Month 12Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports